There is a need for new therapeutic paradigms that can result in sustained treatment-free remission.

Our goal is to provide patient-centric solutions to achieve durable clinical responses and withdrawal of immunosuppressive medications.

Learn about the different steps involved in a CAR T-cell treatment.

Initial disease targets

Our initial disease targets are autoimmune diseases for which there are no approved treatments, or for which the results of existing treatments could be significantly improved.

Clinical trials currently available or in our immediate pipeline include:

Lupus Nephritis

Systemic Sclerosis

Myasthenia Gravis

Multiple Sclerosis

Patients are our focus

With our platform of targeted cellular therapies, we are working to address the complexities of the immune system as we strive to transform the standard of care with innovative treatment options designed to reset the immune system with a well-tolerated treatment. We hope to shift the therapeutic paradigm so that there is no more incremental disease control through chronic dosing.

Patients with autoimmune diseases treated with KYV-101, have experienced transient and manageable side effects consisting of CRS (fever) and mild ICANS (dysarthria, dysgraphia, and somnolence).1

1. Data on file.